Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207 million public offering of common stock of Denali Therapeutics, including the full exercise by the underwriters of their option to purchase additional shares of common stock. Denali Therapeutics common stock is listed on the Nasdaq Global Select Market under the symbol “DNLI.”

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases. Denali Therapeutics is based in South San Francisco, California.

The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Scott A. Blumenkranz, Dana Lueck-Mammen and Paula Gergen. The tax team included partner Rachel D. Kleinberg and associate Adam R. Brownstone. Partner David R. Bauer, counsel Bonnie Chen and associate Jennifer Leather provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post